A meta-analysis of bevacizumab plus interferon alfa for previously untreated patients with metastatic clear-cell renal carcinoma (mRCC).

@article{Likun2011AMO,
  title={A meta-analysis of bevacizumab plus interferon alfa for previously untreated patients with metastatic clear-cell renal carcinoma (mRCC).},
  author={Zhou Likun and Yi Ba},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 7_suppl},
  pages={366}
}
  • Zhou Likun, Yi Ba
  • Published 2011 in
    Journal of clinical oncology : official journal…
366 Background: mRCC was highly resistant to conventional chemotherapy. Both CALGB study and AVOREN study failed to detect statistic differences in overall survival (OS). To evaluate the effectiveness and adverse-effect of bevacizumab plus IFN-α for untreated mRCC, we performed a meta-analysis. METHODS We searched RCTs that compared bevacizumab plus IFN- alpha with other treatments. For trials without heterogeneity, meta-analysis was carried out by using review manager (Revman 4.2) with fixed… CONTINUE READING